Boston Scientific Corporation has announced that it received U.S. Food and Drug Administration (FDA) approval for expanded labeling of its FARAPULSE™ Pulsed Field Ablation (PFA) System. The updated labeling now includes approval for the system's use in pulmonary vein and posterior wall ablation for patients with persistent atrial fibrillation. This approval is backed by clinical evidence from the ADVANTAGE AF clinical trial, which demonstrated significant safety and effectiveness. The company plans further studies to expand its application in treating complex arrhythmias. Boston Scientific is also anticipating regulatory approvals in Europe, Japan, and China in the near future.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。